IN
INO.US Inovio Pharmaceuticals Inc
- Market cap
- USD 268M
- P/E
- -
- P/B
- 37.18x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INO.US undervalued?
Graham numberThe Graham number of Inovio Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inovio Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Inovio Pharmaceuticals Inc yet.
Inovio Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate…
Full company profileInovio Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inovio Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 35.4M | 42.2M | 30.5M | 4.11M | 7.41M | 1.77M | 10.3M | 832K | 218K | 65.3K | 399K |
| Gross Profit | 35.4M | 42.2M | 30.5M | 4.11M | 7.41M | 1.77M | 10.3M | 832K | -2.91M | 65.3K | - |
| Operating Income | -76.2M | -83.6M | -94.1M | -111M | -124M | -301M | -268M | -144M | -112M | -86.8M | -80.1M |
| EBITDA | -74.1M | -84.7M | -89.8M | -107M | -150M | -297M | -271M | -130M | -104M | -82.0M | -97.9M |
| Net Income | -73.7M | -88.2M | -97.0M | -119M | -166M | -304M | -280M | -135M | -107M | -84.9M | -99.9M |
| EPS | -12 | -13 | -13 | -15 | -13 | -17 | -14 | -6.09 | -3.95 | -1.81 | -1.01 |
| Balance Sheet | |||||||||||
| Total Assets | 174M | 187M | 131M | 144M | 540M | 496M | 349M | 171M | 113M | 74.3M | 60.1M |
| Total Liabilities | 50.3M | 44.8M | 44.1M | 139M | 78.6M | 96.3M | 126M | 53.6M | 44.7M | 50.2M | 94.1M |
| Shareholders' Equity | 123M | 142M | 86.9M | 3.44M | 461M | 400M | 222M | 117M | 68.5M | 24.1M | -33.9M |
| Cash & Short-term Investments | 105M | 127M | 81.2M | 89.5M | 412M | 401M | 253M | 145M | 94.1M | 58.5M | 48.4M |
| Total Debt | - | - | - | 99.5M | 39.0M | 33.0M | 32.1M | 30.2M | 11.9M | 9.37M | 7.28M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -62.6M | -63.2M | -73.6M | -97.9M | -178M | -216M | -216M | -124M | -104M | -88.6M | -73.2M |
| Capital Expenditure | 3.94M | 10.3M | 2.09M | 988K | 1.52M | 1.23M | 969K | 321K | 488K | 286K | 18.67 |
| Free Cash Flow | -66.5M | -73.5M | -75.6M | -98.8M | -179M | -217M | -217M | -125M | -105M | -88.9M | -73.2B |
| Ratios | |||||||||||
| ROE | -59.8% | -61.9% | -111.5% | -3,474.7% | -36.1% | -76.0% | -125.8% | -115.1% | -156.6% | -352.5% | - |
| ROA | -42.5% | -47.1% | -74.0% | -82.9% | -30.8% | -61.2% | -80.3% | -79.0% | -94.7% | -114.3% | -166.1% |
| Net Profit Margin | -208.5% | -208.9% | -318.1% | -2,902.8% | -2,245.4% | -17,109.9% | -2,726.7% | -16,239.9% | -49,254.3% | -130,000.0% | -25,058.5% |
| Debt to Equity | - | - | - | 28.97x | 0.08x | 0.08x | 0.14x | 0.26x | 0.17x | 0.39x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Inovio Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 3.86M | 0.30 | - |
| 2019 | USD 93.2M | 11 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:12 on Jan 25, 2024.
Who owns Inovio Pharmaceuticals Inc
- Insiders 0.32%
- Institutions 33.82%
- Public & others 65.86%
- Shares outstanding 187M
- Free float 187M
Top funds holding INO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Small Cap Growth | 10.8M | 9.83% | +54.93% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 5.54M | 5.03% | +56.72% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.28M | 2.98% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 2.69M | 2.44% | 0.00% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 984K | 0.89% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 492K | 0.45% | +2,049,004.17% | Sep 2026 |
| Abante Quant Value FI | 461K | 0.42% | +32.25% | Aug 2026 |
| iShares Micro-Cap ETF | 254K | 0.23% | 0.00% | Oct 2026 |
| Bridgeway Ultra-Small Company | 173K | 0.16% | 0.00% | Jun 2026 |
| Fidelity Total Market Index | 170K | 0.15% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 116K | 0.11% | 0.00% | Sep 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 92.7K | 0.08% | +1.92% | Oct 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 68.0K | 0.06% | +380.53% | Jun 2026 |
| Vanguard Balanced Index Inv | 45.1K | 0.04% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 42.0K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 30.2K | 0.03% | 0.00% | Sep 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 27.7K | 0.03% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 16.5K | 0.02% | -12.41% | Sep 2026 |
Top institutions holding INO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 8.45M | 7.67% | -9.47% | Jun 2026 |
| Jupiter Topco LLC | 5.17M | 4.69% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.65M | 3.31% | +25.83% | Jun 2026 |
| Boxer Capital Management, LLC | 2.84M | 2.58% | +20.04% | Jun 2026 |
| ADAR1 Capital Management LLC | 2.14M | 1.95% | +45.83% | Jun 2026 |
| Renaissance Technologies Corp | 1.51M | 1.37% | +318.77% | Sep 2026 |
| D. E. Shaw & Co LP | 1.35M | 1.23% | -38.92% | Jun 2026 |
| Two Sigma Investments LLC | 1.24M | 1.13% | +217.58% | Jun 2026 |
| Eversept Partners, LP | 1.04M | 0.94% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 803K | 0.73% | +0.16% | Jun 2026 |
| Millennium Management LLC | 796K | 0.72% | -43.57% | Jun 2026 |
| BlackRock Inc | 779K | 0.71% | +17.65% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 481K | 0.44% | +22.62% | Jun 2026 |
| Caption Management, LLC | 479K | 0.43% | 0.00% | Jun 2026 |
| State Street Corp | 337K | 0.31% | +13.60% | Jun 2026 |
| GSA Capital Partners LLP | 265K | 0.24% | -0.02% | Jun 2026 |
| UBS Group AG | 262K | 0.24% | +5.08% | Jun 2026 |
| Quadrature Capital Limited | 259K | 0.24% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 242K | 0.22% | -15.57% | Jun 2026 |
| Northern Trust Corp | 174K | 0.16% | -41.65% | Jun 2026 |
Inovio Pharmaceuticals Inc company profile
- Company name
- Inovio Pharmaceuticals Inc
- Ticker
- INO.US
- Exchange
- USA Stocks
- Listed since
- Feb 12, 1998
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 112
- Fiscal year end
- December
- Address
- 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
- Phone
- 267 440 4200
- Website
- inovio.com
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals Inc management
10- Dr. Jacqueline E. Shea Ph.D.CEO, President & Director · born 1966
- Mr. Peter D. KiesChief Financial Officer · born 1963
- Dr. Michael Sumner B.S., M.B.A., M.D.Chief Medical Officer & Head of Development · born 1965
- Dr. Laurent M. Humeau Ph.D.Chief Scientific Officer & Chairman of the Scientific Advisory Board · born 1967
- Mr. Robert L. Crotty J.D.General Counsel, Corporate Secretary & Chief Compliance Officer · born 1974
- Ms. Jennie WillsonDirector of Communications
- Mr. E. J. Brandreth MBASenior Vice President of Quality Assurance
- Dr. Jeffrey Skolnik M.D.Senior Vice President of Clinical Development
- Mr. Robert J. Juba Jr.Senior Vice President of Biological Manufacturing & Clinical Supply Management
- Mr. Shawn D. Bridy M.A., M.B.A.Senior Vice President of Business Development